Reduced penetrance of Parkinson’s disease models
Abstract: The etiology and progression of Parkinson’s Disease (PD), the second most prevalent neurological disorder, have been widely investigated for several decades; however, a cure is still lacking. Despite the development of several neurotoxins and animal models to study this rather heterogeneous disease, a complete recapitulation of the neurophysiology and neuropathology of PD has not been fully achieved. One underlying cause for this could be that mutations in PD-associated genes have reduced penetrance. Therefore, the quest for novel PD models is required where a double hit approach needs to be evoked – a combination of genetic alterations and environmental factors need to be accounted for in one unique model simultaneously.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Reduced penetrance of Parkinson’s disease models ; volume:34 ; number:2 ; year:2022 ; pages:117-124 ; extent:8
Medizinische Genetik ; 34, Heft 2 (2022), 117-124 (gesamt 8)
- Urheber
-
Morais, Vanessa A.
Vos, Melissa
- DOI
-
10.1515/medgen-2022-2138
- URN
-
urn:nbn:de:101:1-2022081214063953579914
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morais, Vanessa A.
- Vos, Melissa
Ähnliche Objekte (12)
Reduced habit-driven errors in Parkinson’s Disease
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
Redefinition of Parkinson’s Disease
Models of α-synuclein aggregation in Parkinson’s disease
Neurochemical changes in animal models of Parkinson’s disease
Investigation of pathomechanisms in Parkinson’s disease mouse models
Investigations of Synaptic Alterations in Models of Parkinson’s Disease
Genetic Architecture of Parkinson’s Disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Pharmacological treatment of Parkinson’s disease
Reduced habit-driven errors in Parkinson’s Disease
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
Redefinition of Parkinson’s Disease
Models of α-synuclein aggregation in Parkinson’s disease
Neurochemical changes in animal models of Parkinson’s disease
Investigation of pathomechanisms in Parkinson’s disease mouse models
Investigations of Synaptic Alterations in Models of Parkinson’s Disease
Genetic Architecture of Parkinson’s Disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Pharmacological treatment of Parkinson’s disease
Reduced habit-driven errors in Parkinson’s Disease
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
Redefinition of Parkinson’s Disease
Models of α-synuclein aggregation in Parkinson’s disease
Neurochemical changes in animal models of Parkinson’s disease
Investigation of pathomechanisms in Parkinson’s disease mouse models
Investigations of Synaptic Alterations in Models of Parkinson’s Disease
Genetic Architecture of Parkinson’s Disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease